Considering NF-κB has been viewed as a master regulator in macrophage-related inflammation, these studies support the potential of (10Z)-debromohymenialdisine as a therapeutic agent in the treatment of IBD. This evidence concerns the gene NFKB1 and inflammatory bowel disease.